Elanco Animal Health (ELAN) Asset Writedowns and Impairment (2017 - 2025)
Elanco Animal Health (ELAN) posted Asset Writedowns and Impairment of $47.0 million for Q4 2025, up 95.83% sequentially from $24.0 million in Q3 2025, and up 840.0% YoY from $5.0 million in Q4 2024.
Elanco Animal Health (ELAN) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Elanco Animal Health has reported Asset Writedowns and Impairment for 9 years, with the latest figure at $47.0 million in Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 840.0% year-over-year to $47.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91.0 million (up 75.0% YoY) and the FY2025 annual result came in at $71.0 million, down 12.35% from the prior year.
- Asset Writedowns and Impairment grew to $47.0 million in Q4 2025 per ELAN's latest filing, from $24.0 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $275.0 million in Q2 2021 and troughed at $5.0 million in Q4 2021.
- A 5-year average of $45.8 million and a median of $23.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2021 and 2024: Asset Writedowns and Impairment jumped 9066.67% in 2021, then slumped 81.48% in 2024.
- Over 5 years, Asset Writedowns and Impairment stood at $5.0 million in 2021, then surged by 1080.0% to $59.0 million in 2022, then slumped by 54.24% to $27.0 million in 2023, then tumbled by 81.48% to $5.0 million in 2024, then soared by 840.0% to $47.0 million in 2025.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $47.0 million, $24.0 million, and $5.0 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Dec 31, 2023 | 27.00 Mn |
| Dec 31, 2023 | 27.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2022 | 59.00 Mn |
| Jun 30, 2022 | 59.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 56.00 Mn |
| Sep 30, 2021 | 56.00 Mn |